PURPOSE: To analyze the Radiation Therapy Oncology Group (RTOG) database of patients with glioblastoma and appraise whether outcome was influenced by time to initiation of radiation therapy (RT). PATIENTS AND METHODS: From 1974 through 2003, adult patients with histologically confirmed supratentorial glioblastoma were enrolled onto 16 RTOG studies. Of 3,052 enrolled patients, 197 patients (6%) were either initially rendered ineligible or had insufficient chronologic data, leaving a cohort of 2,855 patients for the present analysis. We selected four patient groups based on the interval from surgery to the start of RT: <or= 2 weeks, 2 to 3 weeks, 3 to 4 weeks, more than 4 weeks to the protocol eligibility limit of 6 weeks. Survival times were estimated by the Kaplan-Meier method. Multivariate analysis incorporated variables of time interval, recursive partitioning analysis (RPA) class, and treatment regimen. RESULTS: No decrement in survival could be identified with increasing time to initiation of RT. Among our four temporal groupings, median survival time was unexpectedly and significantly greater in the group with the longest interval (> 4 weeks) than in those with the shortest delay (<or= 2 weeks): respectively, 12.5 months versus 9.2 months (P < .0001). On multivariate analysis, with overall survival as the end point, time interval more than 4 weeks and lower RPA class were both significant predictors of improved outcome. Treatment regimen was not a significant factor. CONCLUSION: There is no evident reduction in survival by delaying initiation of RT within the relatively narrow constraint of 6 weeks. An unanticipated yet significantly superior outcome was identified for patients for whom RT was delayed beyond 4 weeks from surgery.
PURPOSE: To analyze the Radiation Therapy Oncology Group (RTOG) database of patients with glioblastoma and appraise whether outcome was influenced by time to initiation of radiation therapy (RT). PATIENTS AND METHODS: From 1974 through 2003, adult patients with histologically confirmed supratentorial glioblastoma were enrolled onto 16 RTOG studies. Of 3,052 enrolled patients, 197 patients (6%) were either initially rendered ineligible or had insufficient chronologic data, leaving a cohort of 2,855 patients for the present analysis. We selected four patient groups based on the interval from surgery to the start of RT: <or= 2 weeks, 2 to 3 weeks, 3 to 4 weeks, more than 4 weeks to the protocol eligibility limit of 6 weeks. Survival times were estimated by the Kaplan-Meier method. Multivariate analysis incorporated variables of time interval, recursive partitioning analysis (RPA) class, and treatment regimen. RESULTS: No decrement in survival could be identified with increasing time to initiation of RT. Among our four temporal groupings, median survival time was unexpectedly and significantly greater in the group with the longest interval (> 4 weeks) than in those with the shortest delay (<or= 2 weeks): respectively, 12.5 months versus 9.2 months (P < .0001). On multivariate analysis, with overall survival as the end point, time interval more than 4 weeks and lower RPA class were both significant predictors of improved outcome. Treatment regimen was not a significant factor. CONCLUSION: There is no evident reduction in survival by delaying initiation of RT within the relatively narrow constraint of 6 weeks. An unanticipated yet significantly superior outcome was identified for patients for whom RT was delayed beyond 4 weeks from surgery.
Authors: P J Froud; D Mates; J S Jackson; N Phillips; S Andersen; S M Jackson; C J Bryce; I A Olivotto Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-15 Impact factor: 7.038
Authors: O Vujovic; F Perera; A R Dar; L Stitt; E Yu; S M Voruganti; P T Truong Journal: Int J Radiat Oncol Biol Phys Date: 1998-03-01 Impact factor: 7.038
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Georges Noel; Aymeri Huchet; Loic Feuvret; Jean Philippe Maire; Pierre Verrelle; Emilie Le Rhun; Maud Aumont; François Thillays; Marie Pierre Sunyach; Chantal Henzen; Fernand Missohou; Renaud de Crevoisier; Pierre Yves Bondiau; Philippe Collin; Xavier Durando; Gilles Truc; Christine Kerr; Valérie Bernier; Jean-Baptiste Clavier; David Atlani; Anne D'Hombres; Sandrine Vinchon-Petit; Jean Léon Lagrange; Luc Taillandier Journal: J Neurooncol Date: 2012-06-02 Impact factor: 4.130
Authors: Yaacov Richard Lawrence; Deborah T Blumenthal; Diana Matceyevsky; Andrew A Kanner; Felix Bokstein; Benjamin W Corn Journal: J Neurooncol Date: 2011-04-24 Impact factor: 4.130
Authors: Arif N Ali; Peixin Zhang; W K Alfred Yung; Yuhchyau Chen; Benjamin Movsas; Raul C Urtasun; Christopher U Jones; Kwang N Choi; Jeff M Michalski; A Jennifer Fischbach; Arnold M Markoe; Christopher J Schultz; Marta Penas-Prado; Madhur K Garg; Alan C Hartford; Harold E Kim; Minhee Won; Walter J Curran Journal: J Neurooncol Date: 2018-02-05 Impact factor: 4.130
Authors: Alexander L Chin; Everett J Moding; Sarah S Donaldson; Iris C Gibbs; Scott G Soltys; Susan M Hiniker; Erqi L Pollom Journal: Neuro Oncol Date: 2018-07-05 Impact factor: 12.300
Authors: Christina Leitzen; Hans H Schild; Birgitta Bungart; Ulrich Herrlinger; Christiana Lütter; Thomas Müdder; Timo Wilhelm-Buchstab; Heinrich Schüller Journal: Strahlenther Onkol Date: 2010-11-29 Impact factor: 3.621
Authors: Jay K Nathan; Amanda L Brezzell; Michelle M Kim; Denise Leung; D Andrew Wilkinson; Shawn L Hervey-Jumper Journal: J Neurooncol Date: 2017-07-25 Impact factor: 4.130
Authors: R Bütof; K Kirchner; S Appold; S Löck; A Rolle; G Höffken; M Krause; M Baumann Journal: Strahlenther Onkol Date: 2014-01-12 Impact factor: 3.621